Anti-caking excipients, such as silicon dioxide and calcium silicate, serve the vital purpose of preventing the formation of clumps in powders. By coating particles and reducing the attractive forces between them, these excipients enable easy pouring, accurate dosing, and improved product quality.
The science behind anti-caking excipients involves their ability to disrupt the moisture absorption and cohesive forces among particles. Silicon dioxide, for example, forms a hydrophobic layer around particles, preventing moisture absorption and reducing the likelihood of clumping. This is crucial for maintaining the integrity of powdered substances, ensuring their efficacy and usability
Did you know?
Ever wondered why powdered sugar stays powdery and doesn't turn into a solid block? Anti-caking agents like cornstarch are commonly added to powdered sugar to prevent clumping and ensure it remains easy to sprinkle over your favourite desserts.
Colloidal Silicon Dioxide (Aerosil)
Other products are available based on customer requirements
Answers to common questions about anti-caking excipients and their role in free-flowing pharmaceutical powders.
Colloidal Silicon Dioxide (Aerosil) consists of submicron-sized amorphous silica particles that adsorb onto the surface of larger powder particles. These nanoparticles create physical spacers between particles, reducing interparticulate contact area and van der Waals forces that cause caking. The adsorbed silica layer also absorbs excess moisture that would otherwise promote liquid bridge formation and agglomeration, keeping the powder free-flowing even under humid storage conditions.
As a glidant, Aerosil improves powder flowability by reducing interparticulate friction and filling surface irregularities on larger particles. Its nano-sized particles (7-40 nm) coat the surface of granules and excipients, acting like microscopic ball bearings that allow particles to slide past each other more easily. This ensures uniform die filling during tablet compression, reducing weight variation and improving content uniformity in the final tablets.
Colloidal Silicon Dioxide is typically effective at 0.1-2% w/w of the total formulation weight for anti-caking applications. For most pharmaceutical powders, 0.25-0.5% provides optimal flow enhancement without negatively affecting other properties. Higher concentrations (1-2%) may be needed for highly hygroscopic or cohesive materials, while levels above 3% can cause segregation or dusting issues during handling and processing.
Colloidal Silicon Dioxide improves powder flow through three mechanisms: it reduces interparticular cohesive forces by creating physical separation, it adsorbs surface moisture that would otherwise increase liquid bridging, and it neutralizes electrostatic charges that cause particle aggregation. The result is a measurable improvement in Hausner ratio, Carr index, and angle of repose, transforming cohesive powders into free-flowing materials suitable for high-speed tableting and encapsulation.
Yes, Colloidal Silicon Dioxide is widely recognized as safe for oral pharmaceutical use. It is listed in the FDA Inactive Ingredient Database, meets USP/NF and Ph.Eur. pharmacopeial standards, and has an established acceptable daily intake. It is not absorbed systemically from the gastrointestinal tract and is excreted unchanged, making it suitable for use in tablets, capsules, powders, and suspensions at standard concentration levels.
Colloidal Silicon Dioxide (Aerosil)